Unbound Ritonavir Concentrations in Rat and Human Hepatocytes
- 1 July 2015
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 104 (7) , 2378-2387
Abstract
No abstract availableKeywords
Funding Information
- Agentschap voor Innovatie door Wetenschap en Technologie (SBO-IWT)
This publication has 27 references indexed in Scilit:
- Concentration effect relationship of CYP3A inhibition by ritonavir in humansEuropean Journal of Clinical Pharmacology, 2013
- Rapid Measurement of Intracellular Unbound Drug ConcentrationsMolecular Pharmaceutics, 2013
- The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discoveryNature Reviews Drug Discovery, 2010
- Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich‐cultured rat and human hepatocytesBiopharmaceutics & Drug Disposition, 2010
- Active‐Site Concentrations of Chemicals – Are They a Better Predictor of Effect than Plasma/Organ/Tissue Concentrations?Basic & Clinical Pharmacology & Toxicology, 2010
- The complexities of antiretroviral drug–drug interactions: role of ABC and SLC transportersTrends in Pharmacological Sciences, 2010
- Absorption, Metabolism, and Excretion of Darunavir, a New Protease Inhibitor, Administered Alone and with Low-Dose Ritonavir in Healthy SubjectsDrug Metabolism and Disposition, 2009
- Cellular Accumulation of Cholyl-Glycylamido-Fluorescein in Sandwich-Cultured Rat Hepatocytes: Kinetic Characterization, Transport Mechanisms, and Effect of Human Immunodeficiency Virus Protease InhibitorsDrug Metabolism and Disposition, 2008
- Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in Freshly Isolated Rat HepatocytesDrug Metabolism and Disposition, 2008
- THE BINDING OF DRUGS TO HEPATOCYTES AND ITS RELATIONSHIP TO PHYSICOCHEMICAL PROPERTIESDrug Metabolism and Disposition, 2005